NYXH

Interested in Nyxoah SA? Here are five stocks we like better. Revenue surged as the U.S. launch expanded: Second-quarter worldwide revenue rose 21% sequentially to €7.7 million, including €5.2 million from the U.S. First-half revenue reached €14 million, nearly six times the prior-year period. Nyxoah significantly expanded its commercial footprint: Active U.S. accounts doubled to 180, while patients under prior authorization increased 77% to 427, with a reported 100% approval rate. The company plans to add 15 sales representatives and expects further sequential U.S. revenue growth in the second half. 2026 guidance was largely maintained: Revenue guidance remains €36 million–€40 million and gross-margin guidance 60%–62%; operating-expense guidance rose by €1 million due to a one-time equity-compensation charge. Proposed 2027 Medicare reimbursement rates for Genio procedures would increase 12%–15%. Nyxoah (NASDAQ:NYXH) reported second-quarter worldwide net revenue of €7.7 million, up 21% sequentially from the first quarter, as its U.S. commercial launch continued to expand. U.S. net revenue reached €5.2 million, a 22% increase from the prior quarter, while international revenue rose 19% sequentially to €2.5 million. For the first six months of 2026, worldwide revenue totaled €14 million, compared with €2.4 million in the first half of 2025. Chief Financial Officer John Landry said the nearly six-fold increase was driven primarily by the company’s U.S. commercial launch. → SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control Chief Executive Officer Olivier Taelman said Nyxoah doubled its active U.S. account base during the quarter, activating 89 new high-volume accounts and ending the period with 180 active accounts. The company trained 55 new surgeons in the quarter, bringing its total number of trained surgeons to 262. Nyxoah entered the third quarter with 427 patients actively under prior authorization, up 77% from 241 patients entering the second quarter. Taelman said the company has maintained a 100% prior-authorization approval rate for commercial payers, Medicare Advantage and Medicare patients submitted through the WISeR program. → 3 Drone Stocks That Should Soar After the Summer Slump “Doubling our active account base to 180 high-volume AGNS accounts in a single quarter demonstrates that both facilities and physicians are embracing Genio,” Taelman said, referring to the company’s Genio system for obstructive sleep apnea. The company began the quarter with 40 fully trained sales representatives covering 200 of the 400 highest-volume U.S. hypoglossal nerve stimulation accounts. Nyxoah plans to add 15 representatives, expanding to 55 territories. Taelman said the company expects to have the new hires onboarded by the end of the third quarter, trained in early fourth quarter and fully deployed entering 2027. → The Bitcoin Comeback May Already Be Underway—2 ETFs for Exposure Nyxoah expects its current salesforce capacity to support approximately 225 to 230 active high-volume accounts in the second half of 2026. Rather than pursuing broad account expansion, Taelman said the company’s strategy remains focused on reaching the top 400 high-volume U.S. implanting accounts. In response to an analyst question, Taelman said the company’s active accounts averaged approximately 15% market share, while its more established accounts were above that level. Its top account had surpassed 44% market share, he said. Nyxoah said reimbursement clarity for Genio includes dedicated Medicare C-code C8011, while commercial coverage remains stable through existing CPT codes. Commercial payers represented approximately 85% of the business during the quarter, according to Taelman. The Centers for Medicare & Medicaid Services has proposed increases to 2027 reimbursement for the procedure. Under the proposal, hospital outpatient reimbursement for Genio under C-code C8011 would rise 12% to $35,414 from $31,526. Reimbursement for ambulatory surgical centers would increase 15% to $31,722 from $27,563. Nyxoah did not submit an application for a dedicated Category 1 CPT code at the upcoming September CPT Editorial Panel meeting. Instead, the company said it supports the American Academy of Otolaryngology-Head and Neck Surgery’s effort toward a comprehensive coding approach for hypoglossal nerve stimulation. Taelman said a comprehensive coding outcome, if pursued, would first become effective on Jan. 1, 2029. Second-quarter gross margin was 60%, up from 57% in the first quarter. Research and development expense declined to €9.5 million from €10.1 million a year earlier, while selling, general and administrative expense rose to €15.6 million from €10.7 million, largely reflecting the expansion of the U.S. commercial organization. Operating loss was €20.6 million, compared with €19.9 million in the prior-year quarter. Operating expenses included an approximately €900,000 one-time, non-cash share-based compensation charge related to the repricing of employee equity incentive awards. Non-GAAP cash operating expenses were €21.8 million, essentially unchanged from €21.7 million in the first quarter, but up from €19.8 million in the second quarter of 2025 due to investment in the U.S. commercial organization. During the quarter, Nyxoah secured $110 million in financing, consisting of a $95 million equity raise and a $15 million drawdown under the second tranche of its European Investment Bank loan. Cash, cash equivalents and financial assets totaled about €97.8 million as of June 30. Full-year 2026 worldwide revenue guidance was maintained at €36 million to €40 million. Gross-margin guidance remained 60% to 62%. Total operating-expense guidance increased by €1 million to €99 million to €102 million because of the one-time share-based compensation charge. Non-GAAP cash operating-expense guidance remained €88 million to €90 million. Landry said the revenue outlook implies €22 million to €26 million of revenue in the second half of 2026. The company expects U.S. revenue to rise sequentially in both the third and fourth quarters, while international revenue is expected to remain consistent with first-half levels. Taelman said Nyxoah is finalizing 12-month data from its ACCESS study and plans to submit a PMA supplement by the end of the third quarter or, at the latest, early in the fourth quarter. The company expects to present CCC data during the International Sleep Surgery Society Congress after receiving acceptance for a podium presentation. Nyxoah expects an FDA decision on the supplement around the end of the first quarter of 2027, or the beginning of the second quarter at the latest. International revenue nearly doubled in the first half of 2026 compared with the first half of 2025, according to Taelman. In Germany, Nyxoah said it has achieved stable overall market share of up to 25%, with share above 50% at its top high-volume accounts. The company also cited market share above 50% in its initial U.K. accounts, continued expansion in the Middle East, where it is the sole AGNS provider, and a recent entry into the Netherlands. Nyxoah said it intends to maintain financial discipline internationally while pursuing growth and break-even operations in those markets, a milestone it said it has already achieved in Germany. Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company's primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality. The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Nyxoah Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Nyxoah SA (NASDAQ:NYXH) delivered a second consecutive quarter of more than 20% sequential US revenue growth, with US net revenue reaching EUR5.2 million, up 22% from Q1 2026. The company significantly strengthened its balance sheet by securing $110 million in financing during the quarter, removing the near-term financial overhang and providing capital to accelerate its US commercialization ramp. Nyxoah SA (NASDAQ:NYXH) saw strong commercial execution in the US, doubling its active account base to 180 and training 55 new surgeons, bringing the total to 262 trained surgeons. The company reported a 77% increase in patients actively under prior authorization, reaching 427 entering Q3, a key leading indicator for continued launch momentum. CMS proposed meaningful reimbursement increases for the Genio procedure, including a 12% increase for hospital outpatient payments and a 15% increase for ambulatory surgical centers for 2027. International revenue grew 19% sequentially, with the company nearly doubling its first-half 2026 international revenue compared to the first half of 2025, and achieving break-even in Germany. Nyxoah SA (NASDAQ:NYXH) continues to incur significant operating losses, with a total operating loss of EUR20.6 million in Q2 2026, remaining relatively flat year-over-year. SG&A expenses increased substantially to EUR15.6 million in Q2 2026, up from EUR10.7 million in Q2 2025, driven by the continued buildout of the US commercial organization. The company recorded a one-time non-cash share-based compensation charge of approximately EUR900,000 in Q2 2026 due to the repricing of employee equity incentive awards. Nyxoah SA (NASDAQ:NYXH) chose not to submit Genio for a dedicated Category 1 CPT code for the September CPT editorial panel meeting, instead supporting a comprehensive AGNS coding approach, which may delay potential coding clarity. The company's gross margin, while improved to 60% in Q2, remains well below its long-term target of above 80%, indicating ongoing production and scaling challenges. The company expects a significant step-up in operating expenses in the second half of 2026, particularly in Q4, as it expands its US sales force from 40 to 55 territories. Warning! GuruFocus has detected 5 Warning Signs with NYXH. Is NYXH fairly valued? Test your thesis with our free DCF calculator. Q: Can you provide additional color on how you expect the remainder of the year to break out between Q3 and Q4, and your confidence level in achieving the full-year revenue guidance? A: CFO John Landry confirmed the company is comfortable with the full-year guidance of EUR36 million to EUR40 million, which implies a second-half revenue range of EUR22 million to EUR26 million. He expects U.S. revenue to grow sequentially from Q2 to Q3 and again from Q3 to Q4, while international revenue is expected to remain consistent in the back half of the year compared to the first half. Q: On the DREAM study, are you still on track for initial data at the ISSS meeting and the PMA supplement for label expansion? A: CEO Olivier Taelman provided positive updates, stating the company is finalizing the 12-month data and preparing for the PMA supplement submission. The CCC data has been accepted for a podium presentation at the ISSS Congress. The submission is planned for end of Q3 or beginning of Q4, with an expected FDA review period of 180 days, leading to a potential positive result and CCC label expansion by end of Q1 or beginning of Q2 2027. Q: How should we think about the cadence of prior authorizations from start to finish, and how quickly do they convert to actual implants? A: CEO Olivier Taelman noted that entering Q3, the company had 427 patients under prior authorization, a 77% increase from the 241 entering Q2. He explained that while it's not an exact science, the majority of prior authorizations typically convert to actual implants in the following quarter, as evidenced by approximately 240 devices sold in Q2, which aligns with the roughly 240 prior authorizations transferred from Q1. Q: Out of the 180 active sites, what does the approximately 240 implants in Q2 translate to in terms of market share, and are the remaining sites contributing? A: CEO Olivier Taelman stated that the company maintains an average 15% market share in sites where it is present, despite opening 89 new sites in Q2. Importantly, the longest-standing accounts are showing market shares above 15%, with the top account already exceeding 44% market share, demonstrating growing confidence and reordering in Genio. Q: Can you confirm that Nyxoah did not pair with Inspire for the C code submission for the September editorial meeting, and what is the strategy? A: CEO Olivier Taelman confirmed this is correct. Nyxoah participates as an industry partner supporting the AAO-HNS led discussion on comprehensive AGNS coding. The company did not submit for a dedicated code in September, choosing to support the comprehensive coding approach instead. Q: What should we expect in terms of new center additions per quarter in the back half of the year, and how will utilization track? A: CEO Olivier Taelman explained that with 40 sales reps covering approximately 5 high-volume accounts each, the company can cover up to 200 sites. With 180 active accounts exiting Q2 and plans to hire 15 additional reps (bringing total to 55), the company expects to reach 225-230 accounts in the second half of 2026. The strategy remains focused on going deep in the TOP400 high-volume accounts rather than expanding to 1,000 accounts. Q: Can you help us think through the moving pieces to hit the gross margin guidance, and where will the incremental OpEx spend come from in the second half? A: CFO John Landry explained that gross margin improvements will be driven by ongoing projects, including the removal of a component (ES) from the device in the second half and continued yield improvements. Regarding OpEx, he anticipates a sequential step-up in Q3, with more significant expenditures in Q4 when the full quarter's worth of U.S. sales rep expansion is baked in, to reach the full-year cash OpEx guidance of EUR88-90 million. Q: What is your strategy regarding the reimbursement coding landscape, given that your competitor has submitted for a dedicated code in September? A: CEO Olivier Taelman stated that the current reimbursement environment is stable and supportive, with Genio having a dedicated C-code (C8011) and 100% prior authorization approval. He noted that the AAO-HNS is leading constructive discussions with AMA on comprehensive AGNS coding, which could be effective January 1, 2029. Nyxoah's strategy remains unchanged, supporting the comprehensive coding approach, and the company sees no risk given the existing coding in place. Q: How is the hiring of the next tranche of 15 sales reps progressing, and when will they be fully productive? A: CEO Olivier Taelman stated that there is high demand from salespeople wanting to join Nyxoah. The company expects to have all 15 onboarded by the end of Q3, with training beginning in Q4. This will allow them to start selling during Q4, with a fully trained sales force of 55 people in place by January 1, 2027. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results U.S. commercial execution driving continued launch momentum resulting in 22% sequential U.S. revenue growth in Q2 2026 over Q1 2026 Mont-Saint-Guibert, Belgium – August 5, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the second quarter and first half of 2026. Financial and Operating Highlights Financials Leading U.S. commercial indicators U.S. reimbursement landscape Hosted investor day on July 8 – Link to the replay “The doubling of active accounts in Q2 and the strong acceleration of our patient pipeline, demonstrate the growing acceptance and excitement around Genio by physicians and patients,” commented Olivier Taelman, Chief Executive Officer of Nyxoah. “With a dedicated Genio C-code for Medicare patients and another quarter of 100% prior-authorization approval for commercial and WISeR patients, we are confident that the current reimbursement landscape supports our accelerating U.S. revenue growth. The recent closing of our $110 million financing provides the capital needed to further invest in Genio’s U.S. commercial organization in the second half of 2026.” Results for the Three and Six Months Ended June 30, 2026 Revenue Net revenue in the second quarter of 2026 was €7.7 million, compared to €1.3 million in the second quarter of 2025. Net revenue in the first half of 2026 was €14.0 million, as compared to €2.4 million for the first half of 2025. The increases in net revenue were primarily driven by the continued expansion of U.S. commercialization activities following FDA approval in August 2025, as well as growth in international markets. Cost of Goods Sold Cost of goods sold was €3.1 million for the second quarter of 2026, resulting in gross profit of €4.6 million and a gross margin of 60% for the second quarter of 2026, compared to cost of goods sold of €0.5 million in the second quarter of 2025, resulting in gross profit of €0.9 million and a gross margin of 63% in the second quarter of 2025. The increase in cost of goods sold was primarily driven by an increase in revenue. The decrease in gross margin was primarily due to a higher mix of U.S. revenue. Cost of goods sold in the first half of 2026 was €5.8 million, as compared to €0.9 million for the first half of 2025, resulting in gross profit of €8.2 million and a gross margin of 59% in the first half of 2026, compared to gross profit of €1.5 million and a gross margin of 63% in the first half of 2025. The decrease in gross margin was primarily due to production yield issues in the first quarter of 2026 and higher mix of U.S. revenue. Research and Development For the second quarter of 2026, research and development expenses were €9.5 million, versus €10.1 million for the second quarter of 2025. For the first half of 2026, research and development expenses were €18.3 million, versus €19.0 million for the first half of 2025. The decreases in research and development expenses were primarily due to a decrease in product development expenses. Selling, General and Administrative For the second quarter of 2026, selling, general and administrative expenses were €15.6 million, versus €10.7 million for the second quarter of 2025. For the first half of 2026, selling, general and administrative expenses were €31.0 million, versus €23.1 million for the first half of 2025. The increases in selling, general and administrative expenses were primarily driven by the continued build-out of the Company’s U.S. commercial organization, including sales, marketing, and market access functions. Operating Loss Total operating loss for the second quarter of 2026 was €20.6 million, versus €19.9 million in the second quarter of 2025. Total operating loss for the first half of 2026 was €41.1 million, versus €40.5 million in the first half of 2025. The increases in operating loss reflect increased net revenue offset by increased investments to support the build-out of the Company’s U.S. commercial organization. Cash PositionCash and cash equivalents and financial assets totaled €97.8 million at June 30, 2026, compared to €48.0 million at December 31, 2025. Financial Guidance for the full year 2026 The Company continues to expect worldwide net revenue for the full year 2026 to be in the range of €36 million to €40 million. The Company continues to expect gross margin for the full year 2026 to be in the range of 60% to 62%. The Company now expects total operating expenses for the full year 2026 to be in the range of €99 million to €102 million. This increase of approximately €1 million is due to the one-time share-based compensation expense of approximately €0.9 million associated with the repricing of employee equity incentive arrangements recorded in the second quarter. The Company continues to expect non-GAAP cash operating expenses for the full year 2026 to be in the range of €88 million to €90 million. Non-GAAP cash operating expenses reflect expected total operating expenses less non-cash expenses such as depreciation, amortization, and share-based compensation. Conference call and webcast presentation Company management will host a conference call to discuss financial results on Wednesday, August 5, 2026, beginning at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q2 Earnings Call Webcast. For those not planning to ask a question to management, the Company recommends listening via the webcast. If you plan to ask a question, please use the following link: Nyxoah's Q2 2026 Earnings Call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call. The archived webcast will be available for replay shortly after the close of the call. Non-GAAP financial measuresThis press release includes non-GAAP (Generally Accepted Accounting Principles) financial measures, including non-GAAP cash operating expenses. Non-GAAP cash operating expenses are calculated by excluding from GAAP certain operating expense items, including depreciation, amortization, capitalized research and development expenses, impairment losses on intangible assets, and share-based compensation. These non-GAAP financial measures are presented because the Company believes they are useful indicators of its operating performance. Management uses these non-GAAP financial measures as measures of the Company's operating performance and for planning purposes, including the preparation of the Company's annual operating budget and financial projections. The Company believes these measures are useful to investors as supplemental information because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. These non-GAAP financial measures should not be considered alternatives to, or superior to, any other performance measure derived in accordance with GAAP. They should not be construed to imply that the Company's future results will be unaffected by unusual or non-recurring items. The Company's definitions of non-GAAP cash operating expenses are not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation. About NyxoahNyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study in 2024 and receipt of approval from the FDA in August 2025. For more information, please visit http://www.nyxoah.com. Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device. Forward-looking statements Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company's results of operations, financial condition, liquidity, performance, prospects, growth, future revenue, future operating expenses, future gross margins and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2026 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS (unaudited) (in thousands) Non-GAAP Financial Measures The following table contains a reconciliation of GAAP operating expenses to non-GAAP cash operating expenses for the three and six months ended June 30, 2026 and 2025, respectively. Contacts: NyxoahJohn Landry, [email protected] Rémi RenardHead of Investor Relations & Corporate Communication [email protected] Attachment ENGLISH_Nyxoah_Q2 2026 Earnings PR_FINAL

Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026 Mont-Saint-Guibert, Belgium – July 27, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the second quarter of 2026 on Wednesday, August 5, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q2 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the following link: Nyxoah's Q2 2026 Earnings Call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call. The archived webcast will be available for replay shortly after the close of the call. About NyxoahNyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study in 2024 and receipt of approval from the FDA in August 2025. For more information, please visit http://www.nyxoah.com. Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device. Forward-looking statements Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company's results of operations, financial condition, liquidity, performance, prospects, growth, future revenue, future operating expenses, future gross margins and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2026, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Contacts:NyxoahJohn Landry, [email protected] Rémi RenardHead of Investor Relations & Corporate [email protected] Attachment ENGLISH_2Q26_Earnings_Call_Announcement

Nyxoah Announces Preliminary Results for the Second Quarter of 2026 Continued U.S. launch momentum drives second quarter global preliminary net revenue of €7.7 millionCMS proposes 2027 OPPS and ASC payment increase of 12% and 15% respectively Mont-Saint-Guibert, Belgium – July 7, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported certain preliminary unaudited second quarter 2026 financial and operating results. Second Quarter 2026 – Preliminary Sales and Market Metrics Financials Leading U.S. commercial indicators Reimbursement US Liquidity "We closed Q2 with clear U.S. momentum: the scaling of our U.S. sales force allowed us to double the number of active accounts to 180 high-volume HGNS accounts and deliver a second consecutive quarter of over 20% sequential U.S. revenue growth. Additionally, the recent CMS proposed reimbursement increases in both hospital outpatient and ambulatory surgical centers are among the strongest within APC 5465 (Level 5 Neuromodulation) and, if approved, support continued economic value for the Genio procedure,” commented Olivier Taelman, Nyxoah's Chief Executive Officer. “With $110 million in new financing, the financial overhang is now behind us, and we are positioned to accelerate Genio's U.S. commercial ramp and drive toward profitability." Revenue Guidance for the Full Year 2026 The Company continues to expect global net revenue for the full year 2026 to be in the range of €36 million to €40 million. The preliminary, unaudited revenue results and cash, cash equivalents and financial assets described in this press release are estimates only and are subject to revision until Nyxoah reports its full financial results for the second quarter of 2026, including in its Quarterly Report on Form 6-F. Upcoming Investor and Analyst Day The Company will be hosting an Investor and Analyst Day on Wednesday, July 8, 2026, in New York. The event will be held at the offices of Bank of America and will run from 10:00 AM to 12:30 PM ET (16:00 to 18:30 CET). The event will be webcast live for those unable to attend in person, with a replay available shortly afterwards. Participants joining via the webcast will be able to ask questions during the event. Event details Date: Wednesday, July 8, 2026 Time: 10:00 AM to 12:30 PM ET (16:00 to 18:30 CET) Location: Bank of America Tower at One Bryant Park, 1111 Avenue of the Americas, New York, NY Registration and webcast access: https://www.netroadshow.com/events/login/1PeTHmohOsvcptHhJ0ULn0T429N8JKb3IuZtL About Nyxoah Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65. For more information, please visit http://www.nyxoah.com/. Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device. Forward-looking statements Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company's results of operations, financial condition, liquidity, performance, prospects, growth, future revenue and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2026 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Contacts: NyxoahJohn Landry, [email protected] Rémi RenardHead of Investor Relations & Corporate [email protected] Attachment ENGLISH_Nyxoah Prelim Earnings PR Q2

Nyxoah Welcomes the Flemish Investors Federation (VFB) at LégiaPark following Q1 2026 Results and U.S. Commercial Momentum Mont-Saint-Guibert, Belgium – May 20, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today participated in an exclusive afternoon organized at LégiaPark, the life sciences innovation campus in Liège, Belgium. The event, which took place at LégiaPark alongside neighbouring listed company Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), brought together up to 40 investors and members of the press for a comprehensive update on both companies. Olivier Taelman, Chief Executive Officer of Nyxoah, walked attendees through the strong commercial progress of the Genio® system in the United States, less than a year after FDA approval in August 2025. He also revisited Nyxoah's recently announced LégiaPark investment, a large manufacturing facility designed to scale industrial capacity in line with the Company's growth ambitions. Stijn Van Rompay, Chief Executive Officer of Hyloris, then presented Hyloris' strategy, broad pipeline of innovative drug candidates and its 2025 highlights, before guiding attendees through the company's R&D facilities and illustrating the depth of the life sciences ecosystem developing on the LégiaPark campus. “Welcoming the VFB community at LégiaPark today was an opportunity to share the tangible progress Nyxoah is delivering in the United States, less than a year after FDA approval, and to demonstrate the strength of the Belgian industrial footprint we are building to support our growth,” commented Olivier Taelman, Chief Executive Officer of Nyxoah. Located on the heights of Liège, LégiaPark is establishing itself as a benchmark life sciences cluster in Wallonia, now home to two Belgian-listed companies on a single campus. About Nyxoah Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and received approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65. For more information, please visit http://www.nyxoah.com/. Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device. Forward-looking statements Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company's results of operations, financial condition, liquidity, performance, prospects, growth, future revenue, future operating expenses, future gross margins and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2026 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Contacts:NyxoahJohn Landry, [email protected] Rémi RenardHead of Investor Relations & Corporate [email protected] Attachment ENGLISH_Nyxoah Event with VFB Press Release

Interested in Nyxoah SA? Here are five stocks we like better. Nyxoah’s U.S. Genio launch is gaining traction, with first-quarter 2026 worldwide net revenue up 13% sequentially and U.S. revenue rising about 25% to EUR 4.3 million. The company added 15 sales reps, bringing its U.S. field force to 40, and reported 91 active accounts plus 207 surgeons trained. Reimbursement remains strong and is a major focus, with management saying commercial coverage is broad and stable and that reviewed prior authorization submissions were approved at a 100% rate. The company also said Medicare claims received 100% approval under CMS’ WISeR program and noted recent coding clarity for hypoglossal nerve stimulation procedures. Nyxoah expects accelerating growth but margins were pressured in Q1, guiding for 25% to 30% sequential U.S. revenue growth in Q2 and full-year 2026 worldwide net revenue of EUR 36 million to EUR 40 million. Gross margin fell to 57% due to production yield issues, though management expects improvement later in 2026 and further margin expansion in 2027. Nyxoah (NASDAQ:NYXH) reported 13% sequential worldwide net revenue growth in the first quarter of 2026, driven primarily by continued adoption of its Genio system in the United States, where the company is in its second full quarter of commercialization. Chief Executive Officer Olivier Taelman said the company delivered on its commitment to generate 25% sequential U.S. revenue growth from the fourth quarter of 2025 to the first quarter of 2026. He cited momentum across surgeon training, account activation, prior authorization submissions and procedure volumes. → Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe? “The U.S. launch remains the primary driver of our worldwide revenue growth and our key priority,” Taelman said. Nyxoah said U.S. net revenue totaled EUR 4.3 million in the first quarter, up about 25% from EUR 3.4 million in the fourth quarter of 2025. Worldwide gross revenue was EUR 6.7 million before EUR 300,000 in deferrals related to disposable patches delivered over time, resulting in net revenue of about EUR 6.4 million. → MercadoLibre Boldly Invests in Growth: Discount Deepens Taelman said Nyxoah expanded its U.S. commercial field presence by adding 15 sales representatives, bringing the company to 40 fully operational sales reps entering the second quarter. That footprint allows the company to cover 200 of the 400 high-volume hypoglossal nerve stimulation accounts beginning in the second quarter, he said. As of March 31, the company reported several launch metrics: 207 surgeons trained on the Genio system, including 62 trained during the first quarter. 91 active accounts out of 125 targeted accounts, after activating 34 new accounts in the quarter. 241 new patients submitted under prior authorization and still pending at quarter-end. An estimated 12% to 14% average market share in accounts where Nyxoah is already active. → MP Materials Is Quietly Building a Rare Earth Powerhouse Taelman said active accounts are defined as having trained surgeons and value analysis committee approval. In the question-and-answer portion of the call, he said the company had about 116 patients under prior authorization at the end of the fourth quarter of 2025, compared with 241 at the end of the first quarter. He said commercial payers have up to 30 days to respond, and procedures are generally performed one to three months after approval depending on operating room and surgeon availability. Nyxoah executives spent a significant portion of the call discussing reimbursement for hypoglossal nerve stimulation procedures. Taelman said commercial payers represented about 90% of the company’s first-quarter cases, while Medicare represented about 10%. For commercial payers, Taelman said coverage is “broad and stable,” with Genio claims processed under CPT code 64568 or CPT code 64582 depending on payer policy and case review. He noted that UnitedHealthcare recently added CPT 64568 back to its hypoglossal nerve stimulation policy alongside CPT 64582. Taelman said Nyxoah maintained a 100% approval rate on reviewed prior authorization submissions through the end of the first quarter. He also said the company achieved a 100% approval rate for submitted Medicare patients under CMS’ WISeR program, an AI-supported prior authorization tool being rolled out in six states since Jan. 1, 2026. On Medicare, Taelman said CMS provided clarity on Feb. 26 by issuing hypoglossal nerve stimulation-specific C codes for facilities. Claims for Genio implantations are submitted under C code C8011, which Taelman said maps to APC level 5 at EUR 31,526 in the hospital outpatient setting and EUR 27,563 in the ambulatory surgery center setting. Physician fee claims continue to be submitted under CPT 64582 at $722, he said. Looking beyond 2026, Taelman said the CPT Editorial Panel has indicated it does not intend to leave any hypoglossal nerve stimulation technology without appropriate coding. He said the company sees two potential paths for 2028: dedicated CPT codes for different technologies or a comprehensive coding set for hypoglossal nerve stimulation. Nyxoah will take its lead from specialty societies, including AAO-HNS, he said. Internationally, Taelman said first-quarter revenue was consistent with the fourth quarter of 2025, which he described as a strong result given the typical sequential decline from the fourth quarter to the first quarter. Growth was supported by performance in Germany, continued therapy adoption in the Middle East and entries into the U.K. and the Netherlands. Taelman also said the company remains focused on a disciplined financial approach, pointing to Germany as an example where Nyxoah reached break-even three years after launch. Chief Financial Officer John Landry said gross margin was 57% in the first quarter, down from 62% in the first quarter of 2025. He attributed the decline to production yield issues during the quarter, which he said have been addressed. During the Q&A session, Landry said some impact from the issue will continue into the second quarter as units produced in the first quarter flow through the income statement. He said gross margin should return to the 63% to 64% range in the back half of 2026. Nyxoah expects full-year gross margin of 60% to 62%. Landry said the company expects a step-up in margin in early 2027 with the Genio 2.2 upgrade, including a new disposable patch and activation chip. He said the upgrade is expected to move gross margin into the low 70% range, with longer-term gross margins expected to exceed 80% as implant cost reductions take effect. Nyxoah guided for second-quarter U.S. net revenue growth of approximately 25% to 30% sequentially from the first quarter. For full-year 2026, the company expects worldwide net revenue of EUR 36 million to EUR 40 million. Landry said sequential U.S. growth is expected to accelerate in the second half of the year, with growth in the low-40% to 45% range in the third quarter and in the 50% range in the fourth quarter. He said the fourth quarter is typically seasonally stronger in the U.S. as patients have exhausted deductibles. Operating expenses were EUR 24.2 million in the first quarter, compared with EUR 21.4 million a year earlier. Non-GAAP cash operating expenses were EUR 21.7 million, compared with EUR 19.5 million in the prior-year period. Landry said the increase reflected investment in the U.S. commercial organization, including sales, marketing and market access. Nyxoah ended the quarter with EUR 25.9 million in cash, cash equivalents and financial assets. The company expects to draw approximately EUR 13.8 million from the second tranche of its European Investment Bank loan in the second quarter. Landry said Nyxoah believes it can reach revenue break-even below EUR 150 million in revenue while managing operating expenses and investing in growth. Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company's primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality. The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Nyxoah Q1 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for May 2026.

This article first appeared on GuruFocus. Release Date: May 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Nyxoah SA (NASDAQ:NYXH) achieved a 25% sequential U.S. revenue growth in Q1 2026 compared to Q4 2025, indicating strong execution of their U.S. launch. The company trained 62 new surgeons in Q1, bringing the total to 207 surgeons trained on the GENIOS system, enhancing their market presence. Nyxoah SA (NASDAQ:NYXH) maintained a 100% approval rate on reviewed prior authorization submissions, showcasing effective market access strategies. The company expanded its U.S. commercial field presence with 15 additional sales reps, enabling coverage of up to 200 high-volume accounts. International revenue remained consistent with Q4 2025, avoiding the typical sequential decline, and showing strong performance in markets like Germany and the Middle East. Gross margin decreased to 57% in Q1 2026 from 62% in Q1 2025 due to production yield issues, which have been addressed. Operating expenses increased to EUR 24.2 million in Q1 2026 from EUR 21.4 million in Q1 2025, driven by investments in the U.S. commercial organization. The company faces ongoing challenges with Medicare, which only represents approximately 10% of their cases, due to initial coding uncertainties. Despite the growth, Nyxoah SA (NASDAQ:NYXH) is still not at break-even, with a revenue target of EUR 150 million needed to achieve this. The company anticipates a slight gross margin impact in Q2 2026 due to units built in Q1 running through the P&L, delaying full margin recovery. Warning! GuruFocus has detected 4 Warning Signs with NYXH. Is NYXH fairly valued? Test your thesis with our free DCF calculator. Q: Can you discuss the confidence in achieving the full-year 2026 revenue guidance, especially considering the ongoing reimbursement situation? A: Olivier Talman, CEO: We have added 50 new sales reps, bringing the total to 40, which allows us to cover 200 out of 400 high-volume accounts. Surgeons are gaining experience, and we have 91 active accounts out of 125 targeted sites. We also have 241 patients submitted for prioritization, which gives us confidence in achieving strong double-digit growth, especially in the second half of the year. John Landry, CFO, added that revenue growth is expected to accelerate in the back half of the year, with sequential growth rates increasing from 25%-30% in Q2 to 40%-50% in Q4. Q: What is the strategy for obtaining a permanent CPT code for Genio, and how does it relate to the recent AMA CPT panel meeting? A: Olivier Talman, CEO: For 2026, reimbursement is clear with CMS C codes and commercial payer coverage under CPT codes 64568 and 64582. For 2027, we expect no change on the Medicare side, and commercial codes may migrate to 64582. By 2028, there could be dedicated CPT codes for all AGNS technologies or a comprehensive AGNS coding set. We are prepared for both scenarios and will follow the lead of specialty societies. Q: Can you provide details on the 241 patients submitted under prior authorization and the approval process timeline? A: Olivier Talman, CEO: At the end of Q1 2026, we had 241 patients submitted, up from 116 at the end of Q4 2025. Commercial payers have up to 30 days to approve, and we have maintained a 100% prior authorization approval rate. The timeline for getting patients through the approval process varies from one to three months, depending on surgical scheduling and site volume. Q: What are the expectations for gross margin improvement, and how does it relate to production yield issues? A: John Landry, CFO: We experienced production yield issues in Q1, which have been resolved. We expect gross margins to improve starting in Q2 and continue throughout the year. The Genio 2.2 upgrade in early 2027 will further enhance margins, moving them from the low 60s to north of 70%. Long-term, we aim for gross margins over 80% through cost reductions and volume-based pricing with contract manufacturers. Q: How does the dynamic between Genio and Inspire 5 play out in terms of device selection at sites? A: Olivier Talman, CEO: Our strategy involves partnering with sleep physicians for patient selection and management. Most patients arrive at hospitals seeking AGNS solutions, not specifically Genio. Once at the site, they are informed of their options, and many choose Genio due to its features like no implanted battery and bilateral stimulation. We focus on high-volume implanters and involve sleep physicians from the start, which has been effective in driving adoption. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

REGULATED INFORMATION Nyxoah Reports First Quarter 2026 Financial and Operating Results Strong Genio launch in the U.S. drove 25% sequential quarterly U.S. revenue growth Continued clarity around HGNS and Genio reimbursement in the U.S. Mont-Saint-Guibert, Belgium – May 12, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the first quarter of 2026. Q1 2026 Financial and Operating Highlights Financials U.S. net revenue first quarter 2026 was €4.3 million (gross revenue was €4.5 million), 25% sequential growth over net revenue fourth quarter 2025 Global net revenue first quarter 2026 was €6.4 million (gross revenue was €6.7 million), 13% sequential growth over net revenue fourth quarter 2025 Leading U.S. commercial indicators 62 new surgeons trained in Q1, bringing the total to 207 surgeons trained 34 new accounts activated in Q1, bringing the total to 91 active high-volume accounts 241 patients submitted under prior authorization and still pending at the end of Q1 U.S. reimbursement landscape – further clarified Medicare issued new C-Codes covering Genio and clarified facility and physician payments Commercial payers continued reimbursement under existing CPT codes 100% prior-authorization approval obtained on reviewed submissions with commercial payers and WISeR program As of March 31, 2026, cash, cash equivalents and financial assets amounted to €25.9 million. In the second quarter of 2026, the Company expects to draw €13.8 million from the second tranche of the European Investment Bank loan. “Our first quarter revenue results reflect strong execution of our U.S. launch. The 25% sequential quarterly revenue growth was driven by continued strong activity in existing sites, and high growth in new site openings. We continue to see a consistent reimbursement landscape and had a 100% approval rate on closed U.S. prior authorization submissions as of the end of Q1 2026. Reimbursement did not hinder our first quarter results,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer. “Entering our third full quarter of U.S. commercialization, we remain focused on further expanding account activation, treating more patients in active accounts and maintaining operating discipline to deliver sustainable revenue growth in the U.S.” Results for the Three Months Ended March 31, 2026 Revenue Gross revenue for the first quarter of 2026 was €6.7 million before €0.3 million of deferred revenue mainly related to disposable patches which are delivered over time. Net revenue was €6.4 million, compared to €1.1 million in the first quarter of 2025. The increase in net revenue was primarily driven by the continued expansion of U.S. commercialization activities following FDA approval in August 2025, as well as growth in international markets. Cost of Goods Sold Cost of goods sold was €2.7 million for the first quarter of 2026, resulting in a gross profit of €3.6 million and a gross margin of 57%, compared to cost of goods sold of €0.4 million and a gross margin of 62% in the first quarter of 2025. The increase in cost of goods sold was driven by higher volumes associated with the U.S. commercialization. The decrease in gross margin reflects production yield issues which have been addressed. Research and Development For the first quarter of 2026, research and development expenses were €8.8 million, versus €9.0 million for the first quarter of 2025. The decrease in research and development expenses reflects reduced investments in clinical study costs such as DREAM and ACCCESS. Selling, General and Administrative For the first quarter of 2026, selling, general and administrative expenses were €15.4 million, versus €12.4 million for the first quarter of 2025. The increase in selling, general and administrative expenses was primarily driven by the continued build-out of the Company’s U.S. commercial organization, including sales, marketing, and market access functions. Operating Loss Total operating loss for the first quarter of 2026 was €20.5 million, versus €20.6 million in the first quarter of 2025. The change in operating loss reflects increased net revenue offset by increased commercial investments to support U.S. launch activities, as well as continued investment in research and development. Cash Position Cash, cash equivalents and financial assets amounted to approximately €25.9 million at March 31, 2026. In the second quarter of 2026, the Company expects to draw €13.8 million from the second tranche of the European Investment Bank loan. Financial Guidance for the Second Quarter of 2026 and Full Year 2026 The Company expects U.S. net revenue for the second quarter of 2026 to grow sequentially by approximately 25-30% over the first quarter of 2026. The Company expects worldwide net revenue for the full year 2026 to be in the range of €36 million to €40 million. The Company expects the gross margin for the full year 2026 to be in the range of 60% to 62%. The Company expects total operating expenses for the full year 2026 to be in the range of €97 million to €99 million. The Company expects non-GAAP cash operating expenses for the full year 2026 to be in the range of €88 million to €90 million. Non-GAAP cash operating expenses reflect expected total operating expenses less non-cash expenses such as depreciation, amortization, and share-based compensation. Conference call and webcast presentation Company management will host a conference call to discuss financial results on Tuesday, May 12, 2026, beginning at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q1 2026 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the following link: Nyxoah's Q1 2026 Earnings Call Q&A Link. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call. The archived webcast will be available for replay shortly after the close of the call. Non-GAAP financial measures This press release includes non-GAAP (Generally Accepted Accounting Principles) financial measures, including non-GAAP cash operating expenses. Non-GAAP cash operating expenses are calculated by excluding from GAAP certain operating expenses items, including depreciation, amortization, capitalized research and development expenses, impairment losses on intangible assets, and share-based compensation. These non-GAAP financial measures are presented because the Company believes they are useful indicators of its operating performance. Management uses these non-GAAP financial measures as measures of the Company's operating performance and for planning purposes, including the preparation of the Company's annual operating budget and financial projections. The Company believes these measures are useful to investors as supplemental information because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. These non-GAAP financial measures should not be considered alternatives to, or superior to, any other performance measure derived in accordance with GAAP. They should not be construed to imply that the Company's future results will be unaffected by unusual or non-recurring items. The Company's definitions of non-GAAP cash operating expenses are not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation. About Nyxoah Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65. For more information, please visit http://www.nyxoah.com/. Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device. Forward-looking statements Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company's results of operations, financial condition, liquidity, performance, prospects, growth, future revenue, future operating expenses, future gross margins and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2026 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS (unaudited) (in thousands) For the Three Months Ended March 31, Non-GAAP Financial Measures The following tables contain a reconciliation of GAAP operating expenses to non-GAAP cash operating expenses for the three months ended March 31, 2026 and 2025, respectively. Contacts: Nyxoah John Landry, CFO [email protected] Rémi Renard Head of Investor Relations & Corporate Communication [email protected] Attachment ENGLISH_Earnings PR 1Q26